The clinical and prognostic significance of CMTM6/PD-L1 in oncology

• Mahmoud Mohammad Yaseen ^[1] ; Nizar Mohammad Abuharfeil ^[1] ; Homa Darmani ^[1]
  1. [1] Jordan University of Science and Technology

     Jordan University of Science and Technology

     Jordania

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 8, 2022, págs. 1478-1491
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor and immune cells has opened new horizons for investigating the role of CMTM6/CMTM4 in different aspects of oncology including their clinical and prognostic values in different cancer types. The absence of a specific review article addressing the available results about the clinical and prognostic roles of CMTM6 alone and/or in combination with PD-L1 in cancer has encouraged us to write this paper.